Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial of ifinatamab ...

The progress the UK has made as a global contributor to clinical trials is “remarkable”, says former health minister Lord ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.